

Please note: This document was created automatically and is not a substitute for the manufacturer's original document.

Product Datasheet

Anti-Human IFN-beta Antibody, Rabbit, Polyclonal ABT-ABG10161-U100

Article Name	Anti-Human IFN-beta Antibody, Rabbit, Polyclonal
Biozol Catalog Number	ABT-ABG10161-U100
Supplier Catalog Number	ABG10161-U100
Alternative Catalog Number	ABT-ABG10161-U100-100UG
Manufacturer	Abcepta
Host	Rabbit
Category	Antikörper
Application	ELISA, IHC, WB
Species Reactivity	Human
Clonality	Polyclonal
Purity	Produced from sera of rabbits pre-immunized with highly pure recombinant Human IFN-beta. Anti-Human IFN-beta specific antibody was purified by affinity chromatography employing immobilized Human IFN-beta matrix.
Form	A sterile filtered antibody solution was lyophilized from PBS, pH 7.2.
Antibody Type	Polyclonal Antibody

Application Notes

WesternBlot: To detect Human IFN-beta by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 µg/ml. When used in conjunction with compatible secondary reagents, the detection limit for recombinant Human IFN-beta is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.. Sandwich: To detect Human IFN-beta by sandwich ELISA (using 100 µl/well antibody solution) a concentration of 0.5 - 2.0 µg/ml of this antibody is required. This antigen affinity purified antibody, in conjunction with BioGems Biotinylated Anti-Human IFN-beta (60-181BT) as a detection antibody, allows the detection of at least 0.2 - 0.4 ng/well of recombinant Human IFN-beta.. Immunohistochemistry: This antibody stained formalin-fixed, paraffin-embedded sections of human normal placenta. The recommended concentration is 0.75µg/ml with an overnight incubation at 4°C. An HRP-labeled polymer detection system was used with a DAB chromogen. Heat induced antigen retrieval with a pH 6.0 sodium citrate buffer is recommended. Optimal concentrations and conditions may vary.

 Tissue samples were provided by the Cooperative Human Tissue Network, which is funded by the National Cancer Institute. . Neutralization: To yield one-half maximal inhibition [ND50] of the biological activity of Human IFN-beta (5.00µg/ml), a concentration of 2.5 µg/ml of this antibody is required.. Reconstitution: Centrifuge vial prior to opening. Reconstitute in sterile water to a concentration of 0.1-1.0 mg/ml.